NASDAQ$ASPI
ASP Isotopes Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close
Briefing
ASP Isotopes Inc reported total revenue of $4.18 million and a net loss attributable to shareholders of $6.88 million for the first quarter ended March 31, 2026.
The company achieved revenue growth driven by its radiopharmacy operations and new LNG sales following the Renergen acquisition. However, it recorded a significant operating loss of $24.89 million due to increased research and development and selling expenses. The quarter also saw the deconsolidation of Skyline and continued investment in isotope enrichment facilities.
- Revenue increased to $4.18 million from $1.10 million year-over-year.
- Net loss attributable to shareholders was $6.88 million or $(0.06) per share.
- Acquired Renergen adding helium and LNG segment with $0.59 million revenue.
- Strong cash position of $207.3 million supports ongoing development.
Headline financials
Revenue & EPS history
ASP Isotopes Inc · Revenue · Quarterly
$4.18M
Revenue by segment
ASP Isotopes Inc · $4.18M total across 3 segments · Q1 2026
- Specialist Isotopes and Related Services$3.39M—81.0%
- Helium and LNG$594K—14.2%
- Nuclear Fuels$200K—4.8%
Forward guidance
The company targets initial commercial shipments of enriched C-14 and Yb-176 in Q3 2026 and Si-28 around mid-year 2026 while advancing uranium enrichment initiatives.
Tailwinds
- Strong cash reserves of over $290 million including short-term investments.
- Successful integration of Renergen and deconsolidation of Skyline.
- Progress on multiple enrichment facilities in South Africa.
Headwinds
- Continued net losses and negative operating cash flow.
- Regulatory and construction risks for new facilities.
- Dependence on future capital raises and partnerships.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q1 2026
-3.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
13%
1 / 8 earnings
Positive
+11.7%
Q1 2024
Best reaction
-11.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | +31.6% | +36.1% | |
| Q4 2025 | -3.4% | -1.8% | +13.0% | |
| Q3 2025 | -11.4% | -20.1% | -18.9% | |
| Q2 2025 | -4.2% | -19.5% | -20.5% | |
| Q1 2025 | -6.9% | +14.2% | +3.9% | |
| Q3 2024 | -8.2% | +5.6% | -44.9% | |
| Q2 2024 | -2.8% | +21.8% | +26.1% | |
| Q1 2024 | +11.7% | +35.5% | +1.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro